Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

DIASYS DIAGNOSTIC SYSTEMS

Develops, manufactures, and distributes diagnostic systems for clinical chemistry and immunoturbidimetry. Supplies hi... read more Featured Products: More products

Download Mobile App





DiaSys Presents New Assays and Clinical Chemistry Analyzers at MEDICA 2022

By LabMedica International staff writers
Posted on 14 Nov 2022

DiaSys Diagnostic Systems GmbH (Holzheim, Germany) is presenting its new assays to determine HDL and LDL-cholesterol, alongside the respons®940, the new member of the company’s family of clinical chemistry analyzers, at MEDICA 2022. The MEDICA 2022 Trade Fair is being held in Düsseldorf, Germany from 14-17th November. More than 5,000 exhibitors from 70 countries are presenting their newest products and ideas at MEDICA which draws 120,000 trade visitors from over 170 countries every year.

At this year’s edition of MEDICA, DiaSys is exhibiting respons®910, a compact and fully-automated bench top clinical chemistry analyzer designed for maximum efficiency. Its high on-board capacity of 30 different methods in mono- or twin-containers and 30 sample positions offer the necessary flexibility for everyday use. The integrated STAT port allows easy loading of emergency samples at any time. The wide range of high-quality clinical chemistry and immunoturbidimetric tests manufactured by DiaSys rounds off the respons®910 system.

DiaSys is also presenting the HDL-c direct FS and LDL-c direct FS, its two innovative new reagents added to its cardiovascular risk assessment portfolio. Both are homogenous assays for direct determination and offer long calibration and onboard stability of up to four months. Combined with wide measuring ranges and good precision at clinical cut-off points, DiaSys assays HDL-c direct FS and LDL-c direct FS are of high value for clinical-chemistry laboratories.

Another highlight at the company’s booth at MEDICA 2022 is the presentation of Procalcitonin FS, an innovative, immunoturbidimetric assay to determine Procalcitonin that offers an excellent alternative to established methods. Procalcitonin FS offers a reliable alternative, when time matters in sepsis management. The fluid-stable, particle enhanced immunoturbidimetric assay is characterized by a good precision at clinical cut-off levels and high prozone security. Procalcitonin FS has good onboard and calibration stability and shows high tolerance to endogenous interferents and common therapeutics used in sepsis management. Additionally, the assay shows good concordance to established methods. Procalcitonin FS, dedicated kits are available for the DiaSys respons® systems and BioMajesty® JCA-BM6010/C.

Related Links:
DiaSys Diagnostic Systems

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.